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ttp://dx.doi.org/10.1016/j.ajpath.2014.12.004During cholestatic liver disease, there is dysregulation in the balance between biliary growth
and loss in bile ducteligated (BDL) rats modulated by neuroendocrine peptides via autocrine/
paracrine pathways. Gonadotropin-releasing hormone (GnRH) is a trophic peptide hormone
that modulates reproductive function and proliferation in many cell types. We evaluated the
autocrine role of GnRH in the regulation of cholangiocyte proliferation. The expression of GnRH
receptors was assessed in a normal mouse cholangiocyte cell line (NMC), sham, and BDL rats.
The effect of GnRH administration was evaluated in normal rats and in NMC. GnRH-induced
biliary proliferation was evaluated by changes in intrahepatic bile duct mass and the expres-
sion of proliferation and function markers. The expression and secretion of GnRH in NMC and
isolated cholangiocytes was assessed. GnRH receptor subtypes GnRHR1 and GnRHR2 were
expressed in cholangiocytes. Treatment with GnRH increased intrahepatic bile duct mass as
well as proliferation and function markers in cholangiocytes. Transient knockdown and phar-
macologic inhibition of GnRHR1 in NMC decreased proliferation. BDL cholangiocytes had
increased expression of GnRH compared with normal rats, accompanied by increased GnRH
secretion. In vivo and in vitro knockdown of GnRH decreased intrahepatic bile duct mass/
cholangiocyte proliferation and ﬁbrosis. GnRH secreted by cholangiocytes promotes biliary
proliferation via an autocrine pathway. Disruption of GnRH/GnRHR signaling may be important
for the management of cholestatic liver diseases. (Am J Pathol 2015, 185: 1061e1072; http://
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Disclosures: None declared.Cholangiocytes, which line the intrahepatic biliary epithe-
lium, play key roles in the modiﬁcation of canalicular bile
and are the target of chronic cholestatic liver diseases (ie,
cholangiopathies). Cholangiopathies are characterized by
dysregulation of the balance between biliary proliferation and
loss, leading to chronic liver injury, liver failure, and, ulti-
mately, liver transplantation.1 Among several gastrointestinal
hormones/peptides regulating biliary functions, secretin is a
key stimulatory factor that promotes ductal secretion and
cholangiocyte proliferation.2,3 Secretin stimulates bicarbonatePathology.
Ray et alsecretion by interaction with its receptor (SR), which causes
phosphorylation of the cAMP-dependent cystic ﬁbrosis
transmembrane conductance regulator (CFTR) with subse-
quent activation of the Cl/HCO3
- anion exchanger 2
(AE2).4e6 Secretin-stimulated ductal secretion increases in
parallel to enhanced biliary hyperplasia but decreases during
biliary damage, suggesting that the secretineSReCFTRe
AE2 axis may be an important functional index/regulator of
changes in biliary proliferation/loss.2,5,7,8
Several animal models including bile duct ligation (BDL)
mimic human cholangiopathies.2,7,8 For example, in rodents
with BDL, there is enhanced proliferation of large cAMP-
dependent cholangiocytes that leads to increased intrahepatic
bile duct mass (IBDM).3,9 The proliferative response of the
biliary epithelium to liver injury is characterized by chol-
angiocytes acquiringneuroendocrinephenotypes,which allows
these cells to secrete a number of peptides and hormones [such
as follicle-stimulating hormone (FSH), secretin, melatonin, and
vascular endothelial factor] that are key for maintaining the
homeostasis of the biliary epithelium by both autocrine/para-
crine mechanisms.3,8,10 In addition, these factors modulate the
liver ﬁbrosis that accompanies the onset of cholestatic liver
diseases.11 The BDL model of cholestatic injury also is char-
acterized by marked hepatic ﬁbrosis, which starts primarily
around the biliary epithelium.12 Activation of hepatic stellate
cells and myoﬁbroblasts contribute to the progression of
ﬁbrosis, although some studies have highlighted the contribu-
tion of cholangiocytes in this process.13
The peptide gonadotropin-releasing hormone (GnRH),
which is synthesized and released from neurons within the
hypothalamus,14 mediates the release of FSH and luteinizing
hormone from the anterior pituitary gland. GnRH exerts its
effects by interacting with two GnRH receptor (GnRHR)
subtypes, GnRHR1 and GnRHR2, which are expressed in
mammals.15 There is evidence of an extrahypothalamic origin
for GnRH as well as an extrapituitary presence of GnRHR in
numerous peripheral tissues including reproductive organs
such as testis, ovary, oviduct, and mammary glands.16 The
mRNA for GnRHRs has been shown to be expressed in
various nonreproductive human tissues such as liver,
pancreas, colon, kidney, heart, and pituitary.17,18 Several
studies have shown that GnRH exerts its cellular functions
both in vivo and in vitro by activation of cAMP levels.19,20
With regard to inositol triphosphate (IP3)-dependent
signaling (an important pathway modulating biliary func-
tion),21,22 some studies have shown that GnRH exerts its ef-
fects by increasing IP3 levels,
23,24 although other studies have
shown that GnRH has no effects on IP3 levels.
25 GnRH has
been shown to promote or inhibit cell proliferation (depending
on the cell type) in various carcinomas of the breast, ovary,
endometrium, pancreas, and liver.26 A study has shown
higher expression of both GnRH and GnRHRs in grade I and
grade II human hepatocellular carcinoma, suggesting modu-
lation of hepatocellular growth by this neuroendocrine hor-
mone.27 However, limited information exists regarding the
cellular localization of GnRH and its receptors in the liver and1062particularly in the biliary epithelium, and the effect of GnRH
on liver pathophysiology.26,28 Thus, we performed studies to
show the paracrine/autocrine role of GnRH in the regulation
of biliary mass in normal and cholestatic BDL rats.
Materials and Methods
Materials
Reagents were purchased from Sigma-Aldrich Co. (St. Louis,
MO) unless otherwise indicated. The rabbit monoclonal anti-
body against GnRHR1 and the mouse monoclonal antibody
against GnRHR2 were obtained from Sigma-Aldrich Co. The
substrate for g-glutamyltranspeptidase, N (g-L-glutamyl)-4-
methoxy-2-naphthylamide, was purchased from Poly-
sciences, Inc. (Warrington, PA). The mouse monoclonal
antibody against proliferating cell nuclear antigen (PCNA)
and the rabbit polyclonal antibody against GnRH were
purchased fromSanta CruzBiotechnology, Inc. (Santa Cruz,
CA). The mouse antibody for cytokeratin-19 was purchased
from Leica Biosystems Newcastle Ltd. (Newcastle, UK).
The RNeasy kit for the puriﬁcation of total RNA, real-time
PCR primers for mRNA analysis, and shRNA constructs
were purchased from Qiagen (Valencia, CA). Primers
for mRNA analysis of GnRHR2, a-smooth muscle actin
(a-SMA), collagen type I a 1, and ﬁbronectin-1, and re-
agents for real-time PCR were obtained from BioRad Life
Sciences (Hercules, CA). GnRH Vivo-Morpholino as well
as mismatched-morpholinos were obtained from Gene
Tools, LLC (Philomath, OR). The Nova Ultra Sirius Red
Stain kit to detect interstitial collagen deposition was pur-
chased from IHC World (Woodstock, MD). The Enzyme
Immunoassay kits to measure intracellular cAMP levels
were purchased from Cayman Chemicals Company (Ann
Arbor,MI). The kits for evaluating IP3 levels (2IP1PEAeIP-
One Elisa Assay) were purchased from Cisbio Bioassays
(Burlington, MA). The EIA kits to measure GnRH levels
were purchased from Phoenix Pharmaceutical Inc. (Burlin-
game, CA). The GnRHR1 antagonist, cetrorelix acetate,
29
was purchased from R&D Systems (Minneapolis, MN).
Animals
Male Fischer 344 rats were purchased from Charles River
(Wilmington, MA) and maintained in a temperature-
controlled environment (20C to 22C) with 12:12-hour
light-dark cycles. Animals were fed standard rat chow and
had access to drinking water ad libitum. We treated normal
rats with saline or GnRH (1.0 mg/day)30 for 1 week by i.p.
implanted Alzet (Cupertino, CA) osmotic minipumps. In
separate experiments, BDL rats (immediately after surgery)2
were treated with Vivo-Morpholino sequences against
GnRH (50-GATCGTTTCCATTCTGTTTGGATGT-30, 1.0
mg/kg body weight/day to reduce the hepatic GnRH expres-
sion) or mismatch-morpholino sequences (50-GAACCTTTC-
GATTCTCTTTCGATGT-30) administered by an implantedajp.amjpathol.org - The American Journal of Pathology
Figure 1 A: Representative immunoﬂuorescence for
GnRHR1 (red) and GnRHR2 (green) in liver sections co-
stained with cytokeratin-19 (CK-19) show their expression
on bile ducts. Receptor and CK-19 localization in bile ducts
are indicated by white arrows. B: Immunohistochemistry
showing the expression of GnRHR1 and GnRHR2 in bile
ducts, the expression increases after bile duct ligation
(BDL) (Table 1). Positive staining for GnRHR1 and GnRHR2
in bile ducts is shown by black arrows. Scale barZ 25 mm
(A). Original magniﬁcation: 40 (B).
GnRH Regulation of Biliary Proliferationportal vein catheter for 1 week.31 In these two groups of
animals, GnRH expression was evaluated by immunohisto-
chemistry in liver sections and enzyme-linked immunosorbent
assay kits in the media of short-term cultures of isolated
cholangiocytes. Before collection of serum, tissue, or liver
perfusion, animals were injected with Euthasol (Fort Worth,
TX) following the regulations of the panel of euthanasia of
American Veterinarian Medical Association and protocols
approved by Baylor Scott & White Institutional Animal Care
and Use Committee. Liver and body weight as well as liver toTable 1 Comparison of Parameters in Different Animal Groups
Parameters Normal rats þ saline Normal rats þ
Body weight (g) 217.7  5.8 (n Z 9) 213.5  2.3 (
Liver weight (g) 8.7  0.7 (n Z 9) 8.5  0.6 (
Liver-toebody weight ratio (%) 4.30  0.2 (n Z 9) 3.9  0.2 (
GnRH (% cholangiocytes) 16.2  0.1 24.5  1.0*
Serum GnRH levels (ng/mL) 1.72  0.4 (n Z 24) 2.63  0.03
IBDM (%) 0.48  0.1 0.71  0.08
GnRHR1 (% cholangiocytes) 6.01  0.3 14.51  1.0*
GnRHR2 (% cholangiocytes) 1.0  0.1 3.02  0.3*
SGPT (U/L) 57.3  2.4 (n Z 12) 52.5  1.8 (
SGOT (U/L) 100.7  3.5 (n Z 12) 111.8  1.9 (
Total bilirubin (mg/dL) <0.1 (n Z 12) <0.1 (n Z 12
ALP (U/L) 305.7  1.7 (n Z 12) 263.7  7 (n
*P < 0.05 versus normal rats.
yP < 0.05 versus normal rats treated with GnRH.
zP < 0.05 versus BDL rats treated with mismatch-Morpholino.
ALP, alkaline phosphatase; SGOT, serum glutamic oxaloacetic transaminase; SG
The American Journal of Pathology - ajp.amjpathol.orgbody weight ratio, an index of liver cell growth including
cholangiocytes,2 was measured in all animals.
Cholangiocyte Puriﬁcation
Pure cholangiocytes (by g-glutamyltranspeptidase histo-
chemistry)32 were isolated by immunoafﬁnity separation using
amonoclonal antibody [IgM;whichwas a gift fromDr. Ronald
A. Faris (Brown University, Providence, RI)] that recognizes
an unidentiﬁed antigen expressed by all intrahepaticGnRH
BDL rats þ mismatch
morpholino
BDL rats þ GnRH
Vivo-Morpholino
n Z 8) 165.3  4.3* (n Z 3) 189.10  2.7y (n Z 3)
n Z 8) 9  0.1 (n Z 3) 8.7  0.5 (n Z 3)
n Z 8) 5.4  0.1y (n Z 3) 4.6  0.3z (n Z 3)
80.2  3.4y 50.4  0.3z
* (n Z 18) 3.82  1.18* (n Z 12) 1.89  0.04z (n Z 12)
* 4.2  0.4y 2.4  0.3z
70.0  3.8y 51.0  3.1z
65.1  1.1y 61.4  1.0z
n Z 12) 286.3  2.5y (n Z 9) 235  1.5z (n Z 9)
n Z 12) 863  2y (n Z 9) 571  3.2z (n Z 9)
) 11.5  1.2y (n Z 9) 4.7  1.3z (n Z 9)
Z 12) 447.3  3.8*y (n Z 9) 360.3  1.5z (n Z 9)
PT, serum glutamate pyruvate transaminase.
1063
Figure 2 A: Administration of gonadotropin-releasing hormone (GnRH) to normal rats enhances intrahepatic bile duct mass (IBDM) compared with saline-
treated rats. Data are means  SEM of 10 cumulative values obtained from two slides for each group. For semiquantitative analysis, see Table 1. Cytokeratin-
19epositive bile ducts are indicated by red arrows. B: PCNA expression increases in cholangiocytes from rats treated with GnRH compared with controls. Data
are means  SEM of ﬁve replicates. CeF: cAMP levels and expression of SR, CFTR, and AE2 increases in cholangiocytes from GnRH-treated rats compared with
control rats. Data are means  SEM of three evaluations. *P < 0.05 versus cholangiocytes from control rats. Original magniﬁcation: 40 (A).
Ray et alcholangiocytes.33 Cell number and viability were assessed by
trypan blue exclusion. The in vitro experiments were per-
formed in our immortalized NMC line.34,35
Evaluation of GnRH Receptor Expression
The expression of GnRHR1 and GnRHR2 was evaluated by
both immunoﬂuorescence and semiquantitative immunohis-
tochemistry in liver sections (4- to 5-mm thick) and by
immunoﬂuorescence36 in NMC smears. Immunoﬂuorescence
in liver sections was performed by simultaneous incubation
with antibodies against GnRHR1 or GnRHR2 together with
an antibody against cytokeratin-19 (a cholangiocyte marker).8
Images were obtained by using Leica AF 6000 Modular
Systems (Leica Biosystems Newcastle Ltd.).
Measurement of Biliary Proliferation, Liver Fibrosis,
and Morphology and Serum Chemistry
Cholangiocyte proliferation was evaluated by measuring
IBDMs in parafﬁn-embedded liver sections (4- to 5-mm thick)
by semiquantitative immunohistochemistry for cytokeratin-
19, a biliary-speciﬁcmarker.8 IBDMwas evaluated as the area
occupied by CK-19 positive bile ducts/total area  100.
Sections were examined with an Image Analysis System
(Delta Sistemi, Rome, Italy). Biliary proliferation also was
evaluated in isolated cholangiocytes by measuring PCNA1064expression by real-time PCR.37 Fibrosis in liver sections was
assessed by Sirius red staining to evaluate interstitial collagen
deposition identiﬁed by red color in 4- to 5-mmethick parafﬁn-
embedded liver sections.38 Changes in the ﬁbrotic reaction in
response to knockdown of GnRH in the liver (by GnRHVivo-
Morpholino) were evaluated by measuring the mRNA
expression of ﬁbrotic markers (ie, ﬁbronectin-1, a-SMA, and
collagen type IaI) in RNA from cholangiocytes and total liver
by real-time PCR.38 All reactions were compared with glyc-
eraldehyde-3-phosphate dehydrogenase to ensure proper RNA
loading. Data were expressed as relative mRNA levels SEM
of PCNA to glyceraldehyde-3-phosphate dehydrogenase ratio.
The morphology of other organs including the liver was deter-
minedbyH&Estaining in 4- to 5-mmethick parafﬁn-embedded
sections. The serumlevels of transaminases (glutamate pyruvate
transaminases and serum glutamic oxaloacetic transaminase),
alkaline phosphatase, and total bilirubin were measured by a
Dimension RxL Max Integrated Chemistry system (Dade
Behring, Inc., Deerﬁeld, IL) at Baylor Scott & White.
Effect of GnRH on cAMP and IP3 Levels, and the
Expression of SR, CFTR, and AE2 in Cholangiocytes
In cholangiocytes from normal rats treated with saline or
GnRH we evaluated intracellular cAMP and IP3 levels and
the expression of SR, CFTR, and AE2 (functional indices of
biliary growth)2,5e7,9 by real-time PCR. After puriﬁcation,ajp.amjpathol.org - The American Journal of Pathology
Figure 3 A: Gonadotropin-releasing hormone (GnRH) expression
decreases in the hypothalamus of normal rats treated with GnRH and in bile
duct-ligated (BDL) rats compared with normal rats, and increases in the hy-
pothalamus of BDL rats treated with GnRH Vivo-Morpholino compared with
BDL control rats. Data are means  SEM of three experiments. B: Represen-
tative immunohistochemistry for GnRH in liver sections from normal and BDL
rats. The immunoreactivity of GnRH increases in bile ducts from BDL compared
with normal rat (Table 1). Red arrows indicate bile ducts showing positivity
for GnRH. C and D: GnRH expression and levels increase in cholangiocytes (C)
and cholangiocyte supernatant (D) from BDL compared with normal rats,
respectively. Data are means  SEM of six evaluations. *P < 0.05 versus
normal rats; yP < 0.05 versus BDL rats. Original magniﬁcation: 40 (B).
GnRH Regulation of Biliary Proliferationcholangiocytes were incubated for 1 hour at 37C33 and
subsequently incubated for 5 minutes (cAMP) or 10 minutes
(IP3) at room temperature before evaluating the levels of
these messengers.9,39
Biliary Expression and Secretion of GnRH
To validate our models, we measured GnRH mRNA
expression in the hypothalamus and cholangiocytes by real-
time PCR, and GnRH levels by EIA kits40 in the serum and
the media of primary cultures (after incubation for 6 hours) of
cholangiocytes from the selected groups of animals. GnRH
expression was evaluated by immunohistochemistry in 4- to
5-mmethick liver sections and by real-time PCR and
immunoﬂuorescence in NMC. The levels of GnRH secreted
from basolateral and apical domains of NMC was measured
by plating the cell lines for 72 hours on collagen-coated ﬁlters
of tissue culture inserts to produce a conﬂuent monolayer.3
In Vitro Effect of GnRH on NMC Proliferation
NMCwere stimulated with 0.2% bovine serum albumin (basal)
or 10 to 100 nmol/L GnRH41 for 48 to 72 hours before
measuring cell growth by MTS [3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium, inner salt] proliferation assays.21 In other experiments,
NMC were treated with bovine serum albumin or 50 nmol/L
GnRH41 for 48 hours before evaluating proliferation by real-
time PCR for PCNA36 and for 5 or 10 minutes before evalu-
ating basal cAMP or IP3 levels, respectively. In separate ex-
periments, NMCwere incubated with 50 nmol/L GnRH in the
absence/presence of 10 nmol/L GnRHR1 antagonist cetrorelix
acetate before evaluating cell proliferation by MTS assays
(48 hours’ incubation). To determine which receptor subtype
mediates GnRH effects, control, siRNA-GnRHR1, or siRNA-
GnRHR2 NMC were treated with bovine serum albumin or
GnRH (50 nmol/L for 48 hours) before measuring cell prolif-
eration by MTS assays. The transient knockdown of GnRHR1
or GnRHR2 in NMCwas evaluated by real-time PCR. In other
experiments, NMC were incubated with cholangiocyte media
fromBDL rats (72 hours’ incubation in the absence/presence of
10 ng/mLGnRH antibody) before evaluating cell proliferation
by MTS assays.
The autocrine role of GnRH in the regulation of NMC
proliferation was evaluated in cells after targeted knockdown
of GnRH. These cell lines were established following a pro-
tocol described previously37 by using SureSilencing shRNA
plasmids (SABiosciences, Valencia, CA) for mouse GnRH,
which also confers resistance to neomycin for the selection of
stably transfected cells. Transfected cells were selected by the
addition of 0.5 mg/mL neomycin into the media, and the se-
lection process was allowed to continue for 3 to 4 weeks.37
Surviving cells (designated shGnRH) were assessed for the
relative expression of GnRH compared with the mock-
transfected control cell line (Neg-transfected) by real-time
PCR, and the clone with the greatest degree of knockdownThe American Journal of Pathology - ajp.amjpathol.orgwas selected for the subsequent experiments. In both shGnRH
and Neg-transfected NMC, we measured cell proliferation by
MTS after incubation for 48 hours. The effect of conditioned
media from shGnRH and Neg-transfected NMC on the pro-
liferation of NMC also was evaluated by MTS assays.21
Statistical Analysis
Data are expressed as means  SEM. Differences between
groups were analyzed by the Student’s unpaired t-test when
two groups were analyzed and by analysis of variance when
more than two groups were analyzed, followed by an
appropriate post hoc test.
Results
Cholangiocytes Express GnRH Receptors
To begin to understand the mechanisms by which GnRH
affects cholangiocyte function, it is important to show the1065
Figure 4 A and B: The administration of gonadotropin-releasing hormone (GnRH)
Vivo-Morpholino to bile duct-ligated (BDL) rats decreases the immunoreactivity of
GnRH in liver sections (red arrows) (Table 1) and GnRH secretion in cholangiocyte
supernatant. CeE: The administration of GnRH Vivo-Morpholino to BDL rats decreases
intrahepatic bile duct mass (IBDM) in liver sections (green arrows; C). Proliferating cell
nuclear antigen (PCNA) expression, and cAMP levels compared with BDL control rats.
n Z 3 (D); n Z 6 (E). *P < 0.05 versus BDL rats treated with mismatch-Morpholino.
Original magniﬁcation: 20 (A and C). CK-19, cytokeratin-19.
Ray et allocalization of GnRH receptors in the biliary epithelium. By
immunoﬂuorescence in liver sections from normal and BDL
rats, we showed the expression of GnRHR1 or GnRHR2, in
bile ducts (Figure 1A). By immunohistochemistry, GnRHR1
and GnRHR2 were expressed by normal bile ducts, expres-
sion that was higher in normal rats treated with GnRH, and in
BDL compared with normal rats (Figure 1B and Table 1); the
biliary expression of GnRHR1 and GnRHR2 decreased in
BDL rats treated with GnRH Vivo-Morpholino compared
with mismatch controls (Table 1). BDL rats treated with
mismatch-morpholino did not show any difference from BDL
rats with respect to the parameters measured here. Therefore,
these terms were used interchangeably.
Measurement of Biliary Proliferation, Liver Fibrosis and
Morphology, Serum Chemistry, cAMP and IP3 Levels,
and Ductal Secretion
There was no signiﬁcant difference in body weight and
liver-toebody weight ratio (an index of liver growth)2 be-
tween normal rats treated with saline or GnRH (Table 1).
Liver-toebody weight ratio increased in BDL compared with
normal rats,2 but decreased in BDL rats treated with GnRH
Vivo-Morpholino compared with BDL controls (Table 1),
conﬁrming the trophic effects of GnRH on the liver.1066We next determined the in vivo effect of GnRH on biliary
growth and the levels of cAMP, SR, CFTR, and AE2
(functional indices of biliary proliferation).2,5,7,42 Adminis-
tration of GnRH to normal rats increased IBDM of chol-
angiocytes (Figure 2A and Table 1) and PCNA expression
in cholangiocytes compared with saline-treated rats
(Figure 2B). In cholangiocytes from normal rats treated with
GnRH, there was an increase in basal cAMP (but not IP3,
not shown) levels, and enhanced expression of SR, CFTR,
and AE2 compared with cholangiocytes from controls
(Figure 2, CeF) showing that GnRH mediates its prolifer-
ative effects by activation of cAMP-dependent signaling.
To evaluate the effect of GnRH on liver morphology,
H&E staining of liver sections was performed; we found no
signiﬁcant changes in the lobular structure and inﬂammation
of normal rats treated with saline or GnRH (not shown). In
BDL rats, we observed reactive mildly inﬂamed portal areas
with biliary proliferation, with no signiﬁcant parenchymal
necrosis or inﬂammation compared with normal rats (not
shown). The livers of BDL rats treated with GnRH Vivo-
Morpholino showed mildly reactive portal tracts with min-
imal duct proliferation and minimal parenchymal necrosis or
inﬂammation (not shown). No signiﬁcant changes in the
structure of other organs including kidney, stomach, intes-
tine, and testicles between the latter two groups of animalsajp.amjpathol.org - The American Journal of Pathology
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Figure 5 A: The administration of gonadotropin-releasing hormone (GnRH) Vivo-Morpholino to bile duct-ligated (BDL) rats decreases the immunoreac-
tivity of interstitial collagen in liver sections evaluated by Sirius red staining compared with BDL rats treated with mismatch-Morpholino. Collagen deposition
around bile ducts is indicated by black arrows. B and C: The administration of GnRH Vivo-Morpholino to BDL rats decreases the expression of a-SMA, collagen
type I a(Col1A1), and ﬁbronectin-1 (Fn-1) in puriﬁed cholangiocytes (B) and total liver tissue (C) compared with BDL control rats. Data are means  SEM of 12
real-time PCR reactions. *P < 0.05 versus BDL rats treated with mismatch-Morpholino. Original magniﬁcation: 20 (A).
GnRH Regulation of Biliary Proliferationwere observed. Treatment of normal rats with GnRH did not
alter the serum levels of alkaline phosphatase, trans-
aminases, or bilirubin compared with control rats (Table 1).
The serum levels of alkaline phosphatase, transaminases,
and bilirubin increased in BDL rats (treated with mismatch-
morpholino) compared with normal rats, but decreased in
BDL rats treated with GnRH Vivo-Morpholino compared
with matched controls (Table 1).
As validation of our in vivo models, there was reduced
GnRH mRNA expression in the hypothalamus of normal
rats treated with GnRH and BDL rats compared with normal
rats, and increased GnRH mRNA expression in the hypo-
thalamus of BDL rats treated with GnRH Vivo-Morpholino
compared with matched controls (Figure 3A). In GnRH-
treated normal rats, there was increased biliary immunore-
activity for GnRH in liver sections, and enhanced GnRH
serum levels compared with control rats (Table 1). We
observed an increase in GnRH serum levels in BDL
compared with normal rats, and a reduced concentration ofThe American Journal of Pathology - ajp.amjpathol.orgserum GnRH in BDL rats treated with GnRH Vivo-
Morpholino compared with matched controls (Table 1).
Role of GnRH in the Autocrine Regulation of
Cholangiocyte Growth
To establish the autocrine role of GnRH in biliary prolifera-
tion, we evaluated the expression and secretion of GnRH in the
selected groups of animals. The immunoreactivity of GnRH
increased in bile ducts from BDL compared with normal rats
(Figure 3B and Table 1). In BDL rats, there was increased
GnRH mRNA expression in cholangiocytes and GnRH
levels in cholangiocyte supernatant compared with normal rats
(Figure 3, C and D). Because the biliary expression/secretion
of GnRH increases after BDL (Figure 3, BeD), we evaluated
the effect of decreased expression of hepatic GnRH (by
administration of GnRH Vivo-Morpholino) in the modula-
tion of biliary hyperplasia during cholestasis. The decrease
of GnRH in BDL rats treated with GnRH-speciﬁc1067
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Figure 6 A: By immunoﬂuorescence, normal mouse cholangiocyte cell line (NMC) expresses both GnRHR1 and GnRHR2. Speciﬁc immunoreactivity of
representative ﬁelds is shown in red and nuclei were stained with DAPI (blue). B: GnRH (10 to 100 nmol/L) induces the proliferation of NMC in a dose-
dependent manner. C: Gonadotropin-releasing hormone (GnRH) increases PCNA expression in NMC compared with basal levels. Data are means  SEM of
ﬁve replicates. D: GnRH (50 nmol/L)-induced increase in NMC proliferation is blocked when NMC are treated with the speciﬁc GnRHR1 antagonist. E: GnRH-
mediated increase in NMC proliferation is preferentially blocked when GnRHR1 is silenced. Basal proliferative activity decreases in si-GnRHR1 NMC compared
with control NMC. Data are means  SEM of ﬁve replicates. F: cAMP levels increase in NMC treated with GnRH. NMC treated with secretin was used as the
positive control. Data are means  SEM of six replicates. *P < 0.05 versus basal (C and E) or versus control NMC (F); yP < 0.05 versus NMC treated with GnRH
alone (B and D) or versus cells treated with control vector and GnRH (E). Scale bar Z 25 mm (A).
Ray et alVivo-Morpholino was shown by immunohistochemistry in
liver sections and enzyme-linked immunosorbent assay kits in
cholangiocyte supernatant (Figure 4, A and B and Table 1).
The administration of GnRH Vivo-Morpholino to BDL rats
signiﬁcantly decreased serum levels of transaminases, alkaline
phosphatase, as well as total bilirubin (Table 1), IBDM
(Figure 4C), PCNA expression (Figure 4D), and cAMP levels
(Figure 4E) compared with matched control rats. Consistent
with previous studies,38,43 we found enhanced ﬁbrosis (evi-
denced by Sirius red staining) in liver sections obtained from
BDL rats treated with mismatch-Morpholino compared with
normal rats (data not shown). Inhibition of the GnRH/cAMP
axis by targeted knockdown of GnRH (by administration
of GnRHVivo-Morpholino) in BDL rats resulted in a decrease
in interstitial collagen deposition as well as reduced expression
of a-SMA, collagen type I a, and ﬁbronectin-1 (Figure 5)
compared with mismatch control rats.
Effect of GnRH on NMC Proliferation and Effect of
Silencing of GnRHR1 and GnRHR2 on GnRH-Induced
NMC Proliferation
To validate the direct proliferative effect of GnRH on chol-
angiocytes, we performed in vitro studies to show that GnRH
stimulates biliary proliferation by interaction with GnRH1068receptors. First, we showed by immunoﬂuorescence that
NMC express both GnRHR1 and GnRHR2 (Figure 6A).
GnRH (10 to 100 nmol/L, 48 and 72 hours) increased the
proliferation of NMC in a dose-dependent manner
(Figure 6B). There also was increased PCNA expression in
NMC treated with GnRH (50 nmol/L, 48 hours) compared
with basal levels (Figure 6C). The GnRH-induced increase in
NMC proliferation was blocked by cetrorelix acetate and by
silencing of GnRHR1, but not GnRHR2 (Figure 6, D and E).
The proliferative effects of GnRH on NMC were associated
with enhanced cAMP levels; secretin (positive control)7,42
also increased cAMP levels of these cells (Figure 6F).
To provide direct evidence of the autocrine role of GnRH
in biliary proliferation, we evaluated the effect of stable
knockdown of GnRH on NMC proliferation. By immuno-
ﬂuorescence, NMC express GnRH (Figure 7A) and secrete
GnRH in both the apical and basolateral domains
(Figure 7B). Incubation of NMC with BDL cholangiocyte
supernatant increased the proliferation of these cells that
was blocked by preincubation with a GnRH-neutralizing
antibody (Figure 7C). We have shown that shGnRH NMC
(approximately 90% knockdown compared with Neg-
transfected NMC) (Figure 7D) showed lower proliferative
activity compared with Neg-transfected NMC (Figure 7E).
The supernatant of shGnRHNMC (containing lower amountsajp.amjpathol.org - The American Journal of Pathology
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Figure 7 A and B: In vitro, normal mouse cholangiocyte cell line (NMC) also express gonadotropin-releasing hormone (GnRH) and secrete GnRH at both the
apical and basolateral domains. C: Incubation of NMC with the media of short-term cultures of bile duct-ligated (BDL) cholangiocytes increases the prolif-
eration of these cells. GnRH-stimulation of NMC proliferation is blocked by preincubation with a GnRH-neutralizing antibody. Data are means  SEM of four
replicates. D and E: The shGnRH NMC (approximately 90% knockdown) shows lower proliferative activity compared with Neg-transfected NMC. Data are
means  SEM of ﬁve replicates. F: The supernatant of shGnRH NMC increases NMC proliferation at a lower extent compared with the supernatant of Neg-
transfected NMC, which display a higher proliferative capacity because they secrete more GnRH. Data are means  SEM of three experiments. *P < 0.05
versus basal; yP < 0.05 versus Neg-transfected NMC. Scale bar Z 10 mm.
GnRH Regulation of Biliary Proliferationof GnRH) increased NMC proliferation at a lower extent
compared with the supernatant of Neg-transfected NMC,
which secrete more GnRH (Figure 7F).
Discussion
Here, we showed the paracrine/autocrine stimulatory role of
GnRH on biliary proliferation in normal and cholestatic rats.
Speciﬁcally, we showed that bile ducts and isolated and
cholangiocyte lines (NMC) express GnRHR1 and GnRHR2.
Administration of GnRH to normal rats increased chol-
angiocyte proliferation and IBDM concomitant with
increased cAMP levels and expression of SR, CFTR, and
AE2. In addition to the hypothalamus, cholangiocytes also
express GnRH and secrete GnRH at both the basolateral and
apical domains. After BDL, there was an increase in GnRH
serum levels that likely was owing to enhanced secretion of
GnRH from cholangiocytes, because there was reduced
expression of GnRH from the hypothalamus. Reduction of
biliary GnRH expression/secretion (by administration of
GnRH Vivo-Morpholino) in BDL rats was associated with
reduced biliary proliferation and cAMP levels. We alsoThe American Journal of Pathology - ajp.amjpathol.orgshowed the following: i) NMCs express GnRHR1 and
GnRHR2; ii) GnRH increased cAMP-dependent prolifera-
tion of NMC, which was prevented by pharmacologic in-
hibition or silencing of GnRHR1; iii) NMCs express and
secrete GnRH; iv) incubation of NMC with the conditioned
media of cholangiocyte cultures increased the proliferation
of these cells, and this increase was prevented by pre-
incubation with a GnRH-neutralizing antibody; v) the su-
pernatant of shGnRH NMC increased NMC proliferation at
a lower extent compared with Neg-transfected NMC; and
vi) shGnRH NMC displayed lower proliferative activity
compared with Neg-transfected NMC.
Several studies have shown that during the progression
of biliary damage (eg, after BDL) cholangiocytes secrete
neuroendocrine factors, which regulate biliary homeostasis
by both autocrine/paracrine mechanisms.10,31,44,45 For
example, whereas secretin, vascular endothelial factor, and
nerve growth factor stimulate biliary proliferation, other
factors including melatonin and serotonin inhibit biliary hy-
perplasia.10,31,44 As validation of our model, the increase in
GnRH serum levels (observed after prolonged GnRH
administration or BDL) likely was owing to enhanced GnRH1069
Ray et albiliary expression because GnRH expression was decreased
in the hypothalamus in these two models, supporting an
autocrine role of GnRH in modulating biliary growth. The
increase in GnRH expression observed in the hypothalamus
in BDL rats treated with GnRH Vivo-Morpholino likely was
owing to a compensatory mechanism because of the reduced
expression/secretion of GnRH in cholangiocytes.
In support of our ﬁndings, GnRH and its receptors were
shown to be present at higher levels in grades I to II he-
patocellular carcinoma cells, suggesting a role for GnRH in
the modulation of hepatocellular carcinoma growth.27
Furthermore, one study showed the presence of GnRHR
in nonreproductive tissues such as human liver, heart, kid-
ney, and pituitary.18 GnRH and its receptors also have been
expressed in the rat gastrointestinal tract, pancreas, and
submaxillary glands.46 A recent study also showed that
cystic ﬁbrosis epithelial cells express GnRHR, and GnRH
improves the chloride transport defect in these cells.47
Supporting the ﬁnding that GnRH improves the chloride
transport defect, we found that GnRH increased cAMP-
dependent expression of SR, CFTR, and AE2. Our data
provide the ﬁrst evidence that GnRH stimulated biliary
proliferation by interacting selectively with GnRHR1 (but
not GnRHR2), supporting the concept that functional type II
receptors are expressed by humans but not rodents.48 This
view also is supported by the fact that administration of
GnRH to normal rats induces an increase in the expression
of GnRHR1 but not GnRHR2 (Table 1). Consistently, acti-
vation of GnRHR2 induces a decrease in proliferation of
SK-OV-3 ovarian cancer cells that were negative for
GnRHR1, but positive for GnRHR2.
49
GnRHR subtypes function via activation of IP3
signaling as well as other pathways such as adenylyl
cyclase/cAMP/protein kinase A.15,50,51 Parallel to the latter
studies, our data showed that GnRH stimulates biliary
proliferation by cAMP-dependent signaling because GnRH
increases in vivo IBDM of large cholangiocytes that
function by activation of cAMP-dependent activation of
SR, CFTR, and AE2. Supporting our concept, GnRH
did not increase IBDM of small cholangiocytes (that
function by activation of IP3/Ca
2þ/CaMK Iedependent
signaling)8,21 and IP3 levels of NMC. Consistent with the
concept that cAMP is key in GnRH-modulation of biliary
growth, we observed increased expression of SR/CFTR/
AE2 that are functional proliferative indices of large,
cAMP-dependent cholangiocytes.2,5,7,42
We next showed that cholangiocytes express/secrete
GnRH, which plays a key trophic role in the maintenance of
bile duct mass. In support of our data, several studies
showed the expression of GnRH in other nonreproductive
epithelia including the pancreas.52 Relevant to our ﬁndings,
depletion of enteric GnRH is found in some patients
suffering from severe gastrointestinal dysmotility.53 How-
ever, because GnRH regulates the synthesis and secretion of
FSH and FSH induces biliary hyperplasia,8 we have to
consider that GnRH effects on biliary proliferation also may1070be mediated partly by enhanced release of FSH. Future
studies are warranted to elucidate this point.
Conclusion
In conclusion, our study provides novel insights into the role
of the GnRH/GnRHR axis in the modulation of biliary
growth/loss in normal and cholestatic diseased conditions.
Thus, this study opens up a possible avenue for targeting
this signaling pathway for treating liver diseases.
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